-
公开(公告)号：DE69526080D1
公开(公告)日：2002-05-02
申请号：DE69526080
申请日：1995-06-22
Applicant: CELLTECH R&D LTD
Inventor： HEAD CLIFFORD , WARRELLOW JOHN , ALEXANDER PETER
IPC: A61K31/44 , A61P11/08 , A61P29/00 , A61P43/00 , C07C43/20 , C07C57/30 , C07C69/76 , C07C205/06 , C07C227/02 , C07C229/44 , C07C233/65 , C07C327/48 , C07D213/30 , C07D213/32 , C07D213/38 , C07D213/61 , C07D213/89
-
公开(公告)号：GB0130563D0
公开(公告)日：2002-02-06
申请号：GB0130563
申请日：2000-06-19
Applicant: CELLTECH R&D LTD
IPC: A61K31/505 , A61K31/506 , A61P9/10 , A61P9/14 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D409/04
Abstract: Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R is a hydrogen atom or a straight or branched chain alkyl group; R is a -X -R group where X is a direct bond or a linker atom or group, and R is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
-
-
-
-
Patent Agency Ranking
公开(公告)号：CA2409617A1
公开(公告)日：2001-12-06
申请号：CA2409617
申请日：2001-05-30
Applicant: CELLTECH R&D LTD
Inventor： LANGHAM BARRY JOHN , HEAD JOHN CLIFFORD , WARRELLOW GRAHAM JOHN , LINSLEY JANEEN MARSHA , PORTER JOHN ROBERT , ARCHIBALD SARAH CATHERINE , ALEXANDER RIKKI PETER
IPC: C07D487/08 , A61K31/47 , A61K31/4709 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P1/04 , A61P3/10 , A61P11/06 , A61P17/06 , A61P19/02 , A61P25/28 , A61P29/00 , A61P37/00 , A61P37/06 , A61P43/00 , C07D471/04 , C07D519/00 , C07D221/00 , A61K31/435
Abstract: 2,7-Naphthyridine containing squaric acids of formula (1) are described, wherein Ar1 is an optionally substituted 2,7-naphthridin-1-yl group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted aromatic or heteroaromatic chain; Alk is a chain (2) in which R is a carboxylic acid (-CO2H) or a derivative or biostere thereof; R1 is a hydroge n atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom or group; Alk1 is an optionally substituted aliphatic chain; n is zero or the integer 1; R2 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, heteropolycycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit t he binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
-
-
-
-
-
-
Search Results
485
records
(took 0.025 seconds)
